Lilly Asia Ventures had contributed to cancer diagnostics technology provider Burning Rock's series C round, which was led by GIC.
China-based oncology diagnostics technology developer Burning Rock closed a RMB850m ($126m) series C round yesterday that included Lilly Asia Ventures (LAV), an investment vehicle for pharmaceutical firm Eli Lilly.
The round was led by GIC, the Singaporean government’s sovereign wealth fund, and also featured investment banking firm CMB International Capital, healthcare fund Lyfe Capital, venture capital firm Sequoia Capital China and T&Brothers Capital.
Burning Rock is working on next-generation sequencing technology to diagnose different types of cancer at an earlier…
